"10.1371_journal.pone.0062264","plos one","2013-11-11T00:00:00Z","Salvatore Siena; Eric Van Cutsem; Mingyu Li; Ulf Jungnelius; Alfredo Romano; Robert Beck; Katia Bencardino; Maria Elena Elez; Hans Prenen; Mireia Sanchis; Andrea Sartore-Bianchi; Sabine Tejpar; Anita Gandhi; Tao Shi; Josep Tabernero","Ospedale Niguarda Ca Granda, Milan, Italy; University Hospitals Leuven and KU Leuven, Leuven, Belgium; Celgene Corporation, Summit, New Jersey, United States of America; Vall dHebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain","Conceived and designed the experiments: SS EVC UJ JT. Analyzed the data: SS EVC ML UJ AR RB HP AG TS JT. Performed the trial/contributed patients: SS EVC KB MEE HP MS ASB ST JT. Wrote/contributed to the manuscript: SS EVC ML UJ AR RB KB MEE HP MS ASB ST AG TS JT.","Salvatore Siena is a member of advisory boards for Sanofi-Aventis, AstraZeneca, Roche, Genentech, and Amgen, and was supported by Oncologia Ca Granda Onlus (OCGO) Fondazione. Eric Van Cutsem has received research funding from Merck-Serono, Roche and Sanofi-Aventis. Andrea Sartore-Bianchi received lecture fees from Merck Serono and Roche, is a member of advisory board for Amgen, and was supported by Oncologia Ca Granda Onlus (OCGO) Fondazione. Josep Tabernero has participated in advisory boards for Amgen, Celgene, Genentech, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Symphogen. Katia Bencardino was supported by Oncologia Ca Granda Onlus (OCGO) Fondazione. Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Anita Gandhi, and Tao Shi are Celgene employees and stockholders. This study was funded by Celgene Corporation. Cetuximab was provided by Merck KGaA. Medical writing services were provided by Kim Grootscholten, MSc, of Excerpta Medica BV, funded by Celgene Corporation. Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Anita Gandhi and Tao Shi are employed by Celgene Coporation. The Lenalidomide (Revlimid®) used in this study is a Celgene Corporation product. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","11","Salvatore Siena","SS",15,TRUE,4,9,10,15,TRUE,TRUE,FALSE,0,NA,FALSE
